Sosei COPD drug Phase III trial meets primary endpoint: Novartis
Novartis has been awarded NVA237’s license by Sosei and its co-development partner Vectura in April 2005. Novartis plans to launch NVA237 as a once-daily monotherapy for COPD in
Exegenesis Bio and Modalis Therapeutics have entered a research partnership and licence agreement to progress MDL-201, a therapeutic candidate for Duchenne muscular dystrophy (DMD).